Ewings sarcoma treatment
Abstract
Combined approach is a standard of treatment of Ewing sarcoma patients. Chemotherapy, radiotherapy, surgery and possible targeted therapy are the main steps of successful treatment. Evolution of chemotherapy is discussed in this literature review.
About the Authors
O. A. Nisichenko
N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
Moscow
M. S. Kubirov
N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
Moscow
S. N. Michailova
N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
Moscow
References
1. Булычева И. Современные критерии прогноза в диагностике первичных опухолей костей. 2013, гл. 7, с. 340.
2. Глеков И.В. Нетрадиционное фракционирование дозы при лучевой терапии солидных опухолей у детей. Автореферат дисс. д-ра мед. наук. М., 1999, 47 с.
3. Глеков И.В., Белова В.П., Григоренко В.А. Конформная терапия в детской онкологии. Онкопедиатрия. 2014, №3, с. 43-44.
4. Долгополов И.С., Менткевич Г.Л. Современное состояние проблемы лечения детей с онкологическими заболеваниями с неблагоприятным прогнозом. Онкология. 2000, т. 2, № 3, с. 207-2011.
5. Дурнов Л.А., Голдобенко Г.В. Детская онкология. 2002, гл. 16, с. 370.
6. Иванова Н.М. Современные возможности и перспективы лечения детей с опухолями семейства саркомы Юинга. Дисс. д-ра мед. наук. М., 2008, 382 с.
7. Максимов А. Лимфоцит как общая стволовая клетка различных элементов крови в эмбриональном развитии и постфетальной жизни млекопитающих. Folia Haematologica 8. 1909, с. 125-134. Hа русском языке: Cell Ther. Transplant. 2009.
8. Мусаев Э.Р. Современные подходы к хирургическому лечению больных опухолями таза. Дисс. д-ра мед. наук. М., 2008, 220 с.
9. Пунанов Ю.А. Оптимизация лечебной тактики у детей с саркомой Юинга и костной ретикулосаркомой. Дисс. канд. мед. наук. Л., 1983, 241 с.
10. -11. Семенова А.И. Саркома Юинга: характеристика заболевания, особенности диагностики, лечебная тактика. Практическая онкология. 2010, т. 11, № 1, с. 45.
11. Соловьев Ю.Н. Саркома Юинга. Вопросы онкологии. 2002, № 1, с. 7-16.
12. Субботина Н.Н. Режимы кондиционирования со сниженной интенсивностью при проведении аллогенной трансплантации гемопоэтических стволовых клеток в детской онкогематологии. Автореферат дисс. канд. мед. наук. М., 2010.
13. Феденко А.А. Таргетная терапия в лечении сарком мягких тканей. Практическая онкология. 2013, т.14, №2, с.122-126.
14. Хмелевская В.Н. Оптимизация лучевой терапии в комбинированном лечении саркомы Юинга у детей и подростков. Дисс. д-ра мед. наук. Обнинск, 2002, 189 с.
15. Bacci G., Mercuri M., Longhi A. et al. Neoadjuvant chemotherapy for Ewing’s tumour of bone: recent experience at the Rizzoli Orthopaedic Institute. Eur. J. Cancer. 2002, v. 38, p. 2243-2251.
16. Bacci G., Picci P., Ferrari S. et al. Neoadjuvant chemotherapy for Ewing’s sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase - results of two sequential studies. Cancer. 1998, v. 82, p. l174-1183.
17. Bacci G., Toni A., Avella M. et al. Long-term results in 144 localized Ewing’s sarcoma patients treated with combined therapy. Cancer. 1989, v. 63, p. 1477-1486.
18. Bernstein M., Kovar H., Paulussen M. et al. Ewing’s sarcoma family of tumors: current management. The Oncol. 2006, v. 11 (5), p. 503.
19. Bernstein M.L., Devidas M., Lafreniere D. et al. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children’s Cancer Group Phase II study 9457 – a report from the Children’s Oncology Group. J. Clin. Oncol. 2006, v. 24, p. 152-159.
20. Burgert E.O., Nesbit M.E., Gamsey L.A. et al. Multimodal therapy for the management of nonpelvic, localized Ewing’s sarcoma of bone: Intergroup Study IESS-II. J. Clin. Oncol. 1990, v. 8, p. 1514-1524.
21. Cangir A., ViettiT.J., GehanE.A. et al. Ewing’s sarcoma metastatic at diagnosis. Results and comparisons of two Intergroup Ewing’s Sarcoma Studies. Cancer. 1990, v. 66, p. 887-893.
22. Clark P.I., SlevinM.L., Joel S.P. et al. A randomized trial of two etoposide schedules in small-cell lung cancer: The influence of pharmacokinetics on efficacy and toxicity. J. Clin. Oncol. 1994, v. 12, p. 1427-1435.
23. Craft A., Cotterill S., Malcolm A. et al. Ifosfiunide-containig chemotherapy in Ewing’s sarcoma: The second United Kingdom Children’s Cancer Study Group and the Medical Research Council Ewing’s Tumor Study. J. Clin. Oncol. 1998, v. 16, p. 3628-3633.
24. Craft AW1, Cotterill SJ, et all Long-term results from the first UKCCSG Ewing’s Tumour Study (ET-1). United Kingdom Children’s Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party. Eur J Cancer. 1997, v. 33 (7) p. 1061-1069.
25. Craft A.W., Cotterill S.J., Bullimore J.A. et al. Long-term results from the first UKCCSG Ewing’s tumor study (ET-l) II. Eur. J. Cancer. 1997, v. 33, p. 1061-1069.
26. Craft A.W., Paulussen M., Douglas C. et al. EICESS 92 – Early results of an international Ewings tumour study II. Med. Pediatr. Oncol. 2000, v. 35, p. 191 abstr.
27. Delattre O., Zucman J., Melot T. et al. The Ewing’s family of tumors – a subgroup of small-round-cell tumors defined by specific chimeric transcripts. New. Engl. J. Med. 1994, v. 4, p. 294-299.
28. Ewing J. Diffuse endothelioma of bone Proc. N.-Y. Path. Soc. 1921, v. 21, p. 17.
29. Felgenhauer J., Hawkins D., PendergrassT., LindsleyK., ConradE.U., Misser J.S. Very intensive, short-term chemotherapy for children and adolescents with metastatic sarcomas. Med. Pediatr. Oncol. 2000, 34.
30. Ferreira C.G., Epping M., Kruyt F.A. et al. Apoptosis: target of cancer therapy. Clin. Cancer Res. 2002, v. 8, p. 2024-2034.
31. Frei E., Canellos G.P. Dose: a critical factor in cancer chemotherapy. Am. J. Med. 1979, v. 69, p. 585-594.
32. Goldie J.H., Coldman A.J. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 1979, v. 63, p. 1727-1733.
33. Goodman J.W., Hodgson G.S. Evidence for stem cells in the peripheral blood of mice. Blood. 1962, v. 19, p. 702-714.
34. Granowetter L., Womer R., Devidas M., Krailo M., Wang C., Bernstein M., Marina N., Leavey P., Gebhardt M., Healey J., Shamberger R.C., Goorin A., Miser J., Meyer J., Arndt C.A., Sailer S., Marcus K., Perlman E., Dickman P., Grier H.E. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children’s Oncology Group Study. J. Clin. Oncol. 2009, v. 20, 27 (15), p. 2536-2541.
35. Grier H.E., Krailo M.D., Tarbell N.J. et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N. Engl. J. Med. 2003, v. 348, No. 8, p. 694-701.
36. Hayes F.A., Thompson E.I., Meyer W.H. et al. Therapy for localized Ewing’s sarcoma of bone. J. Clin. Oncol. 1989, v. 7, p. 208-213.
37. Hosalkar H.S., Dormans J.P. Surgical Management of Pelvic Sarcomas in Children. J. Am. Acad. Orthop. Surg. 2007, v. 15, 4, p. 408-424.
38. Hustu H.O., Holton H., James Jr. D. & Pinkel D. Treatment of Ewing’s sarcoma with concurrent radiotherapy and chemotherapy. Journal of Pediatrics. 1968, v. 73, p. 249-251.
39. Johnson F.R., Roberts K.B. The growth and division of human small lymphocytes in tissue culture: an electron microscopic study. J. Anat. 1964, v. 98, p. 303-311.
40. Jurgens H., Exner U., Gadner H. ct al. Multidisciplinary treatment of primary Ewing’s sarcoma of bone: a 6-year experience of a European cooperative trial. Cancer. 1988, v. 61, p. 23-32.
41. Kolb E.A., Kushner B.H., Gorlick R. et al. Long-term eventfree survival after intensive chemotherapy for Ewing’s family of tumors in children and young adults. J. Clin. Oncol. 2003, v. 21, p. 3423-3430.
42. Kushner B.H., Meyers P.A., Gerald W.L., Healey J.H., La Quaglia M.P., Boland P., Wollner N., Casper E.S., Aledo A., Heller G., et al. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing’s sarcoma, in children and young adults. J. Clin. Oncol. 1995, v. 13 (11), p. 2796-2804.
43. Ladenstein R., Pötschger U., Le Deley M.C., Whelan J., PaulussenM., Oberlin O., van den Berg H., Dirksen U., Hjorth L., Michon J., Lewis I., Craft A., Jürgens H. Primary Disseminated Multifocal Ewing Sarcoma: Results of the Euro-EWING 99 Trial. J. Clin. Oncol. 2010, v. 201, 28 (21), p. 3284-3291.
44. Marina N.M., PappoA.S., Parham D.M. et al. Chemotherapy dose-intensification for pediatric patients with Ewing’s family of tumors and desmoplastic small round cell tumor: A feasibility study at St. Jude Children’s Research Hospital. J. Clin. Oncol. 1999, v. 17, p. 180-190.
45. Meyer W.H., Kun L., Marina N. et al. Ifosfamide plus etoposide in newly diagnosed Ewing’s sarcoma of bone. J. Clin. Oncol. 1992, v. 10, p. 1737-1742.
46. Miser J.S., Krailo M.D., Tarbell N.J. et al. Treatment of metastatic Ewing’s sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide – A children’s Cancer Group and Pediatric Oncology Group study. J. Clin. Oncol. 2004, v. 22, p. 2873-2876.
47. National Cancer Intelligence Network, 2010, http://www.ncin.org.uk.
48. Nesbit Jr. M.E., Gelum E.A., Burgert Jr. E.O. et al. Multimodal therapy for the management of primary, nonmctastatic Ewing’s sarcoma of bone: a long-term follow-up of the first intergroup study II. J. Clin. Oncol. 1990, v. 8, No. 10, p. 1664-1674.
49. Paulussen M., Ahrens S., Dunst J., Winkelmann W., Exner G., Kotz R. Localized Ewing Tumor of Bone: Final Results of the Cooperative Ewing’s Sarcoma Study CESS 86. Journal of Clinical Oncology. 2001, v. 19, No. 6, p. 1818-1829.
50. Paulussen M., Craft A.W., LewisI., Hackshaw A., Douglas C., Dunst J. et al. Results of the EICESS-92 Study: two randomized trials of Ewing’s sarcoma treatment – cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J. Clin. Oncol. 2008, v. 26 (27), p. 4385-4393.
51. Paulussen M., Ahrens S., Burdach S. et al. Primary metastatic (stage IV) Ewing tumor: Survival analysis of 171 patients from the EICESS studies. Ann. Oncol. 1998, v. 9, p. 275-281.
52. Picci P., Bohling T., Bacci G. et al. Chemotherapy induced tumor necrosis as a prognostic factor in localized Ewing’s sarcoma of the extremities. J. Clin. Oncol. 2001, v. 15, p. 1553.
53. Womer R.B., West D.C., Krailo M.D., Dickman P.S. Randomized comparison of every-two-week v. every-three-week chemotherapy in Ewing sarcoma family tumors (ESFT). Journal of Clinical Oncology. 2008, ASCO Annual Meeting Proceedings (Post-Meeting Edition), v. 26.
54. Rosen G., Wollner N. fan C. et al. Proceedings: disease-free survival in children with Ewing’s sarcoma treated with radiation therapy and adjuvant four-drug seqential chemotherapy. Cancer. 1974, v. 33, p. 384-393.
55. Strauss S.J, Mc Tiernan A., Driver D., Hall-Craggs M., Sandison A., Cassoni A.M. et al. Single center experience of a new intensive induction therapy for Ewing, s family of tumors: Feasibility, toxicity, and stem cell mobilization properties. J. Clin. Oncol. 2003, v. 21, p. 2974-2981.
56. Subbiah V., Anderson P. Targeted therapy of Ewing’s sarcoma. Sarcoma. 2011, 686-985.
57. Sutow W.W., Sullivan M.P. Cyclophosphamide therapy in children with Ewing’s sarcoma. Cancer Chemother. Rep. 1962, v. 23, p. 55-60.
Review
For citations:
Nisichenko O.A., Kubirov M.S., Michailova S.N. Ewings sarcoma treatment. Bone and soft tissue sarcomas, tumors of the skin. 2015;(3):40-48. (In Russ.)
Views:
103
Email this article 
